MSTN and sarcopenia: Increased levels of myostatin have been implicated in AIDS patients, sarcopenia, chronic human muscle disuse atropy, glucocorticoid-induced muscle atrophy [37-42] A systemic administration of myostatin also induced cachexia [43] while functional blockage of myosatin by intraperitoneal injection of its antibody increases muscle mass and strength in dystrophic mouse model [44].